Blueberry Therapeutics

Blueberry Therapeutics is a clinical-stage biotechnology company based in Macclesfield, United Kingdom, that develops nanomedicines using a proprietary nanopolymer drug delivery platform to treat dermatological and infectious diseases. The firm focuses on creating topical therapies for conditions such as onychomycosis, athlete’s foot, acne, and atopic dermatitis. By enhancing drug delivery directly into the skin and nails, the technology aims to improve overall efficacy while maintaining patient safety at significantly reduced doses. Operating with a team of 16 employees, the enterprise has raised $23.77 million across five funding rounds, including a recent £750,000 equity finance injection, to advance its clinical pipeline and commercialize over-the-counter products. The organization is backed by institutional investors including Maven Capital Partners, China Medical System, and Medical Incubator Japan. Blueberry Therapeutics was founded in 2011 by Michael John Davies and John Ridden.